Two agents blocking HER2 led to an additional six months of progression-free survival. Side effects were minimal with the addition of pertuzumab. Results published in the New England Journal of Medicine. SAN ANTONIO — Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended...
Wed, Dec 7 2011
Filed under: Filed under: Press Releases, Research, Breast Cancer, Conference, Cancer, teleconference, Media Materials, AACR, American Association for Cancer Research, women, meeting, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, José Baselga, New England Journal of Medicine, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, CLEOPATRA, HER2-Positive